Italia markets close in 7 hours 17 minutes

FTSE MIB
35.366,51
+0,31(+0,00%)
Dow Jones
39.908,00
+349,89(+0,88%)
Nasdaq
16.742,39
+231,21(+1,40%)
Nikkei 225
38.920,26
+534,53(+1,39%)
Petrolio
78,90
+0,27(+0,34%)
Bitcoin EUR
61.050,09
+3.910,01(+6,84%)

NVCR Jan 2025 17.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,6000

0,0000

(0,00%)

In data: 01:09PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in